Chemicals

Amyris to Acquire Sweet-Protein Developer Oobli

Erik LindqvistNovember 16, 20265 min read2 views

At a glance

  • The proposed acquisition would combine Amyris's fermentation manufacturing capacity with Oobli's sweet-protein technology, with closing expected in the coming weeks.
  • Amyris announced it will acquire Oobli, a Davis, California-based developer of fermentation-derived sweet proteins, to pair Oobli's protein expertise with Amyris's manufacturing scale and commercial reach. The transaction is expected to close in the coming weeks, and Oobli's existing customer commitments and brand partnerships are to continue without interruption.
Stainless-steel fermentation tanks and translucent protein-like forms share a clean, softly lit conceptual facility.

Amyris, Inc. announced it will acquire Oobli, Inc., a Davis, California-based developer of fermentation-derived sweet proteins. Amyris, based in Emeryville, California, is a vertically integrated biomanufacturing company. The transaction is expected to close in the coming weeks.

Amyris described the deal as combining its scientific capabilities and manufacturing depth with Oobli's expertise in protein fermentation. The acquisition follows Amyris's expansion earlier this year of manufacturing capacity at its advanced fermentation facility in Barra Bonita, Brazil. Amyris said the move is a strategic commercial and technology expansion intended to accelerate its presence in protein- and peptide-based solutions across end markets.

Oobli's commercial portfolio will be the first to benefit from the combined platform, according to the announcement. For about a decade, Oobli has been refining a fermentation process for producing sweet proteins naturally found in rare fruits and berries near the equator. The portfolio includes Oubli Fruit, Serendipity Berry and Katemfe Fruit Sweet Proteins, known scientifically as brazzein, monellin and thaumatin. According to the announcement, the portfolio has FDA GRAS status as an ingredient and is FEMA GRAS-affirmed for use as a natural flavor.

Kathy Fortmann, Amyris's chief executive officer, said Oobli offers a commercial and technology platform that complements Amyris's own. She said Amyris aims to apply its commercial scale and resources to accelerate what the company calls the sweet revolution. By combining Oobli's protein expertise with Amyris's strain engineering, manufacturing scale and commercial capabilities, Fortmann said, the company sees potential to broaden its work in food and beverage, personal care, flavors and fragrances, agriculture and other markets.

Ali Wing, Oobli's chief executive officer, said the company has pursued a way to deliver sweet taste without trade-offs to health and the environment. Wing said joining Amyris provides the scale and resources to pursue Oobli's ambition of making sweet proteins a global standard in sweetness solutions.

According to Oobli, sweet proteins are hundreds to thousands of times sweeter than sugar, bind directly to sweet taste receptors and are metabolized by the body as protein. Oobli says this allows them to deliver sweetness without gut disruption or blood sugar spikes. The company positions the ingredients for sugar reduction across sports and nutrition, dairy, beverages, chocolate, bakery and confectionery, citing growing consumer awareness of metabolic health and sugar reduction.

Fortmann said biomanufactured solutions tend to succeed when they align with consumer demand and market needs, and she argued that Oobli's platform does so by addressing sweet taste, sugar reduction and clean label at the same time. Amyris said existing customer commitments and brand partnerships will continue to be honored without interruption as the Oobli portfolio expands within the company.

Reported by Erik Lindqvist, Fine and Electronic Chemicals Quality Editor.